Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05551052 · ClinicalTrials.gov registry record
CRC Detection Reliable Assessment With Blood
A clinical trial of Colorectal Cancer and Colon Cancer, sponsored by New Day Diagnostics.
- Active
- Registry status
- 196
- Enrollment target
- 3
- Study locations
NCT05551052 is a study of Colorectal Cancer and Colon Cancer that is active but no longer recruiting, run by New Day Diagnostics. The registered enrollment target is 196 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05551052, a study of Colorectal Cancer and Colon Cancer, is active but no longer recruiting, sponsored by New Day Diagnostics.
- ACTIVE NOT RECRUITING
- Registry status
- 196 participants
- Enrollment target
- 3
- Study locations
Study Summary
The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Next-Gen CRC Screening Test
Study Locations (3)
California
- Gastro SB - Chula Vista
- SDG Clinical Research - San Diego
- Medical Associates Research Group - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05551052
The ClinicalTrials.gov registry entry for NCT05551052 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (87% lower). The listed sponsor is New Day Diagnostics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Next-Gen CRC Screening Test is the first listed.
NCT05551052 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05551052 about?
NCT05551052 is a clinical study titled "CRC Detection Reliable Assessment With Blood". The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.
What is the current status of trial NCT05551052?
This trial is currently active not recruiting. The enrollment target is 196 participants. The study started on 2022-09-08. Estimated completion is 2027-12-31.
What conditions does trial NCT05551052 study?
This clinical trial studies the following conditions: Colorectal Cancer, Colon Cancer, Rectal Cancer, Adenoma, Colon Polyp.
What interventions are being tested in trial NCT05551052?
The interventions under investigation include: Next-Gen CRC Screening Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05551052?
This trial is sponsored by New Day Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05551052 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.